ProCE Banner Activity

My Thoughts on New Approaches to Manage Relapsed/Refractory Myeloma

Clinical Thought
New data for managing lenalidomide-refractory patients, evolving carfilzomib dosing, and CAR T-cell therapy hold significant potential to improve outcomes in relapsed/refractory multiple myeloma.

Released: October 29, 2018

Expiration: October 28, 2019

No longer available for credit.

Share

Faculty

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Celgene

Takeda Oncology

Faculty Disclosure

Primary Author

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji Kumar, MD, has disclosed that he has provided uncompensated consulting for AbbVie, Celgene, Janssen, Merck, and Takeda and funds for research support paid to his institution from AbbVie, Celgene, Janssen, Merck, Roche, Sanofi, and Takeda.